Abiomed has quickly climbed our Big 100 list, landing this year at 90th, and it has done so without major acquisitions. Fueling the global medtech company’s growth is a device with unique indications and a patient-centered business strategy.
More than 60,000 patients have been treated using Abiomed‘s (NSDQ:ABMD) Impella heart pumps – and every time the world’s smallest heart pump is given to someone, CEO Michael Minogue and his management team get an email.
The email, which contains case information and notes from the physician, is just one way that the company seeks to put patients at the center of their business.
The company’s newly-expanded headquarters doubles as a shrine to their patients. Hanging along the walls of nearly every room and hallway are pictures of people who are alive thanks to Abiomed’s devices. Walking through the facility, Minogue stops at each one and recalls their name and story. He says that despite any obstacles Abiomed has faced in the past, it’s the company’s passion for patients that has propelled them to success.